DDInter1544 DDInter785
Prucalopride is a dihydrobenzofurancarboxamide derivative from the benzofurane family that selectively stimulates 5-HT4 receptors and thus, it presents enterokinetic properties. The high selectivity of prucalopride allowed further development as it prevented the cardiac adverse reactions observed due to non-target effects of precedent therapies. Prucalopride was developed by Shire Development LLC and approved for use in Europe in 2009, in Canada on December 7, 2011 and by the FDA on December 17, 2018.
Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fostamatinib has been identified as a potential therapeutic for controlling acute respiratory distress syndrome (ARDS) in patients with severe COVID-19 through its ability to modulate the SYK kinase.[A235008, A235013, A235018]
Fostamatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tofacitinib
Fostamatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ripretinib
Fostamatinib {u} may lead to a major life threatening interaction when taken with {v} Clarithromycin
Fostamatinib {u} may lead to a major life threatening interaction when taken with {v} Berotralstat
Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib
Fostamatinib may lead to a major life threatening interaction when taken with Clarithromycin
Fostamatinib may lead to a major life threatening interaction when taken with Berotralstat